Skip to content

Study · Observational study · n = 204 · 2021

2 results

Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study.

Pusceddu S, Vernieri C, Di Maio M, Prinzi N, Torchio M, Corti F, Coppa J, Buzzoni R, Di Bartolomeo M, Milione M, Regnault B, Truong Thanh XM, Mazzaferro V, de Braud F

Cancers23 Dec 2021Cited by 12 (Europe PMC)

PMID35008233 (opens in a new tab)PMCIDPMC8750688 (opens in a new tab)DOI10.3390/cancers14010069 (opens in a new tab)PepBankPUB-35008233
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

The prognostic role of diabetes mellitus (DM) in advanced enteropancreatic neuroendocrine tumors (NETs) is unclear. Progression free survival (PFS) was assessed in post-hoc analyses of the 96-week, phase III, double-blind, placebo-controlled CLARINET study of lanreotide 120 mg in patients with advanced non-functional enteropancreatic NETs with DM (with/without metformin) and without DM. Of 204 patients, there were 79 with DM (lanreotide, n = 42 {metformin, n = 14}; placebo, n = 37 {metformin, n = 10}) and 125 without DM (lanreotide, n = 59; placebo, n = 66). Median PFS was 96.0 and 98.0 weeks with and without DM, respectively (hazard ratio 1.20 {95% confidence interval 0.79 to 1.82}; p = 0.380). No difference in PFS was observed in lanreotide-treated patients with/without DM (p = 0.8476). In the placebo group, median PFS was numerically shorter with versus without DM (p = 0.052) and was significantly longer in patients with DM and metformin (85.7 weeks) versus without metformin (38.7 weeks; p = 0.009). Multivariable Cox analyses showed that DM at baseline was not associated with PFS (p = 0.079); lanreotide was significantly associated with lower disease progression risk (p = 0.017). Lanreotide efficacy was confirmed in patients with advanced enteropancreatic NETs, regardless of diabetic status; DM was not a negative prognostic factor. A potential antitumor effect of metformin was observed in patients receiving placebo.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In post hoc multivariable analyses of enteropancreatic NET patients, lanreotide was associated with lower disease progression risk (p = 0.017).

    In plain wordsIn enteropancreatic NET patients, lanreotide was linked to lower disease progression risk than placebo in adjusted analyses.

    Peptide
    Lanreotide
    Outcome
    DecreaseAdjusted disease progression risk
    Study

    n = 204

    Comparator
    placebo
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg · 96 weeksAs given in this study (human).

    Measurements

    p value
    0.017
    multivariable Cox analysis, lanreotide vs placebo

    Source sentences

    Summary
    lanreotide was significantly associated with lower disease progression risk (p = 0.017).
    1 context sentence
    Summary · context
    Progression free survival (PFS) was assessed in post-hoc analyses of the 96-week, phase III, double-blind, placebo-controlled CLARINET study of lanreotide 120 mg in patients with advanced non-functional enteropancreatic NETs with DM (with/without metformin) and without DM.
  2. 02HumanObservational studyEfficacy outcome

    Among lanreotide-treated enteropancreatic NET patients, progression-free survival did not differ with versus without diabetes (p = 0.8476).

    In plain wordsAmong lanreotide-treated enteropancreatic NET patients, progression-free survival did not differ between patients with and without diabetes.

    Peptide
    Lanreotide
    Outcome
    No significant changeProgression-free survival by diabetes status
    Study

    n = 101

    Comparator
    lanreotide-treated patients without diabetes
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg · 96 weeksAs given in this study (human).

    Measurements

    p value
    0.8476
    PFS, lanreotide-treated patients with vs without diabetes

    Source sentences

    Summary
    No difference in PFS was observed in lanreotide-treated patients with/without DM (p = 0.8476).
    1 context sentence
    Summary · context
    Progression free survival (PFS) was assessed in post-hoc analyses of the 96-week, phase III, double-blind, placebo-controlled CLARINET study of lanreotide 120 mg in patients with advanced non-functional enteropancreatic NETs with DM (with/without metformin) and without DM.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.